Live

Injectable fillers have become a go-to beauty solution for young people all across Europe. But a recent EU investigation reveals that behind the promise of plump lips and smooth skin, there may be serious risks hiding in plain sight.

Hyaluronic acid – the main ingredient in most dermal fillers – is usually seen as the poster child for modern aesthetic treatments. It’s praised for its ability to hydrate, smooth wrinkles, and contour faces without surgery. While these treatments are technically considered non-invasive, the substances being injected can still carry real health risks.

And it’s not just about how they’re administered. According to a new EU-wide inspection, even products that officially meet regulatory standards can fall short when it comes to safety.

A European check-up on fillers

As part of a joint enforcement campaign, market surveillance authorities from nine EU countries tested 17 different injectable filler products. This didn’t include permanent fillers – only those meant to be absorbed by the body over time.

The results were concerning. While some products passed lab tests with no issue, others revealed potentially dangerous flaws – from toxicological red flags to serious problems with labeling and instructions.

The chemistry you don’t see

The products were tested in certified labs for sterility, presence of endotoxins, cytotoxicity (how they affect human cells), and harmful chemical substances. The good news? All samples were free from microbiological contamination. The bad news? That’s where the good news ends.

Three out of the 17 samples failed initial tests for endotoxins – bacterial toxins that can cause inflammation, fever, or even life-threatening septic shock in extreme cases. One of those samples exceeded acceptable levels even in confirmatory testing.

Another filler sample failed the cytotoxicity test, suggesting it could damage skin cells. In this case, investigators suspected lidocaine – a local anesthetic often added to fillers to reduce pain – might be the issue. While lidocaine itself isn’t banned, improper dosages or unexpected chemical interactions can lead to irritation or allergic reactions.

But the biggest worry came from chemical substances that could have toxic effects at certain concentrations. Four of the tested products contained substances at levels that crossed a safety threshold. Those four – along with the two fillers that failed toxicity and endotoxin tests – were flagged for further in-depth examination.

Missing Labels, Confusing Instructions

The concerns don’t stop at what’s inside the syringe. Clear, accurate labeling and instructions are essential to ensuring safe use – especially for professionals administering the treatment.

Yet over one-third of the tested products (6 out of 17) failed to meet basic packaging and documentation standards. Missing reference numbers, incomplete technical details, and lack of translations into local languages were common problems.

That’s not just an internal market violation – it’s a patient safety issue. Misreading dosage instructions or storing products incorrectly can lead to serious complications. As a result, manufacturers were ordered to fix these compliance gaps.

Market Surveillance Isn’t Just Bureaucracy

This campaign was part of a broader EU initiative to ensure consumer products – from cosmetics to electronics – meet health, safety, and environmental standards across the single market.

According to the European Commission, such coordinated actions aren’t just about protecting consumers; they also help ensure fair competition. Products that don’t meet EU standards not only pose risks – they also give non-compliant companies an unfair advantage over those who follow the rules.

As Vanessa Capurso from the Commission’s Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs put it: “These checks are vital – not just for user safety, but also for transparency and fairness in the marketplace.”

Popularity brings responsibility

With aesthetic procedures growing more common – especially among younger generations – the market for dermal fillers is booming. But rapid growth needs to be matched with tighter oversight. That means keeping a close eye not just on the ingredients, but on the entire supply chain: from manufacturers and distributors to clinics and beauty salons.

In the end, while most of the fillers tested weren’t directly harmful, a few were flagged as potential health hazards. That’s a clear reminder of why EU market surveillance matters – and why the rules around beauty products need to keep pace with the trends.

Written by

Shape the conversation

Do you have anything to add to this story? Any ideas for interviews or angles we should explore? Let us know if you’d like to write a follow-up, a counterpoint, or share a similar story.

Write a counterargument article Write a related article